Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.30 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15241789 | 0.79 | CA1 (0.39) | CA1CA2CA4TRPA1TRPM8 | |
| SCHEMBL12166548 | 0.79 | CA1 (0.39) | CA1CA2CA4TRPA1TRPM8 | |
| SCHEMBL16948272 | 0.79 | CA1 (0.39) | CA1CA2CA4TRPA1TRPM8 | |
| SCHEMBL19197712 | 0.79 | CA1 (0.39) | CA1CA2CA4TRPA1TRPM8 | |
| SCHEMBL13890112 | 0.79 | CA1 (0.39) | EPHX2CA1CA2CA4TRPA1 | |
| SCHEMBL24783669 | 0.78 | EPHX2 (0.38) | EPHX2PLGPLATLMNANCF1 | |
| SCHEMBL8287065 | 0.78 | PLG (0.39) | EPHX2PLGPLATLMNANCF1 | |
| SCHEMBL3536174 | 0.78 | EPHX2 (0.38) | EPHX2PLGPLATLMNANCF1 | |
| SCHEMBL12279488 | 0.76 | CA1 (0.39) | CA1CA2CA4LMNA | |
| SCHEMBL21773610 | 0.76 | CA1 (0.39) | CA1CA2CA4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325932-A1 | 4-PIPERIDYLBENZAMIDES AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325932-A1 | 4-PIPERIDYLBENZAMIDES AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | HSD11B1, HSD3B1, HSD17B1 | EPHX2 1520/4885CA1 4074/4885CA2 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.